Found: 32
Select item for more details and to access through your institution.
A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 5, p. 383, doi. 10.1002/cpdd.260
- By:
- Publication type:
- Article
Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 222, doi. 10.1002/cpdd.94
- By:
- Publication type:
- Article
A Dual PPAR α/γ Agonist Increases Adiponectin and Improves Plasma Lipid Profiles in Healthy Subjects.
- Published in:
- Drugs in R&D, 2006, v. 7, n. 2, p. 99, doi. 10.2165/00126839-200607020-00004
- By:
- Publication type:
- Article
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
- Published in:
- Vascular Health & Risk Management, 2015, v. 11, p. 165, doi. 10.2147/VHRM.S70907
- By:
- Publication type:
- Article
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDLcholesterol, and non-HDLcholesterol in patients with dyslipidemia.
- Published in:
- Vascular Health & Risk Management, 2014, v. 10, p. 279, doi. 10.2147/VHRM.S58694
- By:
- Publication type:
- Article
Prevalence of microalbuminuria and associated risk factors among adult Korean hypertensive patients in a primary care setting.
- Published in:
- Hypertension Research, 2013, v. 36, n. 9, p. 807, doi. 10.1038/hr.2013.44
- By:
- Publication type:
- Article
Efficacy and Safety of Ezetimibe/Simvastatin Versus Simvastatin Monotherapy in Hypercholesterolemic Patients with Metabolic Syndrome.
- Published in:
- Metabolic Syndrome & Related Disorders, 2007, v. 5, n. 1, p. 13, doi. 10.1089/met.2006.0033
- By:
- Publication type:
- Article
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
- Published in:
- Diabetes & Vascular Disease Research, 2011, v. 8, n. 4, p. 262, doi. 10.1177/1479164111418136
- By:
- Publication type:
- Article
Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes.
- Published in:
- Diabetes & Vascular Disease Research, 2011, v. 8, n. 2, p. 160, doi. 10.1177/1479164111406457
- By:
- Publication type:
- Article
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
- Published in:
- 2016
- By:
- Publication type:
- corrected article
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
- Published in:
- Journal of Clinical Investigation, 2015, v. 125, n. 6, p. 2510, doi. 10.1172/JCI80025
- By:
- Publication type:
- Article
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 12, p. 1528, doi. 10.1002/jcph.773
- By:
- Publication type:
- Article
Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 7, p. 765, doi. 10.1002/jcph.278
- By:
- Publication type:
- Article
Effects of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes and an Inhibitor of OATP1B1/3 Transport, on the Single Dose Pharmacokinetics of Anacetrapib.
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 7, p. 746, doi. 10.1002/jcph.97
- By:
- Publication type:
- Article
The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar .
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 5, p. 540, doi. 10.1002/jcph.20
- By:
- Publication type:
- Article
Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 9, p. 1319, doi. 10.1177/0091270010381497
- By:
- Publication type:
- Article
Pharmacokinetics of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 3, p. 406, doi. 10.1177/0091270010369240
- By:
- Publication type:
- Article
Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D 2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 11, p. 1273, doi. 10.1177/0091270009360042
- By:
- Publication type:
- Article
Effects of Laropiprant, a Selective Prostaglandin D<sub>2</sub> Receptor 1 Antagonist, on the Steady-State Pharmacokinetics of Digoxin in Healthy Adult Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 7, p. 823, doi. 10.1177/0091270009356571
- By:
- Publication type:
- Article
Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist.
- Published in:
- Journal of Clinical Pharmacology, 2009, v. 49, n. 10, p. 1228, doi. 10.1177/0091270009341651
- By:
- Publication type:
- Article
Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin.
- Published in:
- Journal of Clinical Pharmacology, 2009, v. 49, n. 10, p. 1157, doi. 10.1177/0091270009341653
- By:
- Publication type:
- Article
Influence of Taranabant, an Orally Active, Highly Selective, Potent Cannabinoid-1 Receptor (CB1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Plasma Pharmacokinetics.
- Published in:
- Journal of Clinical Pharmacology, 2009, v. 49, n. 1, p. 72, doi. 10.1177/0091270008325930
- By:
- Publication type:
- Article
Interaction of Single-Dose Ezetimibe and Steady-State Cyclosporine in Renal Transplant Patients.
- Published in:
- Journal of Clinical Pharmacology, 2006, v. 46, n. 3, p. 328, doi. 10.1177/0091270005284852
- By:
- Publication type:
- Article
Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2006, v. 46, n. 3, p. 321, doi. 10.1177/0091270005284851
- By:
- Publication type:
- Article
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*<sup>†</sup> The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes
- Published in:
- Journal of Diabetes, 2012, v. 4, n. 3, p. 227, doi. 10.1111/j.1753-0407.2012.00213.x
- By:
- Publication type:
- Article
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
- Published in:
- Lipids in Health & Disease, 2016, v. 15, p. 1, doi. 10.1186/s12944-016-0282-8
- By:
- Publication type:
- Article
A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low-Calorie Diet.
- Published in:
- Obesity (19307381), 2010, v. 18, n. 12, p. 2301, doi. 10.1038/oby.2010.67
- By:
- Publication type:
- Article
Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy.
- Published in:
- Cardiovascular Therapeutics, 2012, v. 30, n. 2, p. 61, doi. 10.1111/j.1755-5922.2010.00181.x
- By:
- Publication type:
- Article